At the outset of the COVID-19 pandemic, the risk that the novel SARS-CoV-2 pathogen presented to pregnant populations was unclear. Evidence of poor maternal and infant outcomes from past outbreaks of viral respiratory illness, including the coronaviruses SARS
1,2 and Middle East respiratory syndrome (MERS),
3 as well as 2009 influenza A(H1N1),
4,5 suggested that SARS-CoV-2 may also differentially affect pregnant individuals. However, international reports have been varied in the degree of illness severity resulting from SARS-CoV-2 infection
6-15 and the degree and nature of associated adverse pregnancy outcomes, such as preeclampsia, preterm birth, stillbirth, and cesarean delivery.
8-11,14 Since existent studies are highly heterogeneous, with many including only cases of COVID-19 identified at the time of hospital admission for obstetric delivery, they may not adequately represent the full effect of SARS-CoV-2 on pregnant populations, which includes infection acquired throughout pregnancy and a range of disease severity. Furthermore, high-quality, population-level data that use contemporaneous comparator cohorts are limited in the literature to date.